Literature DB >> 12698095

Activation of transcription factors AP-1 and NF-kappaB in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation.

Toshihiro Asai1, Tatsuya Nakatani, Satoshi Tamada, Nobuyuki Kuwabara, Shinya Yamanaka, Koichiro Tashiro, Takafumi Nakao, Toshiyuki Komiya, Mikio Okamura, Shokei Kim, Hiroshi Iwao, Katsuyuki Miura.   

Abstract

BACKGROUND: It has been shown that the transcription factors activator protein (AP)-1 and nuclear factor (NF)-kappaB play a pivotal role in various renal diseases. We aimed to study their activations in chronic cyclosporine A (CsA) nephrotoxicity and evaluate the effect of magnesium (Mg) supplementation and blockade of the renin-angiotensin system (RAS), which are known to ameliorate CsA nephrotoxicity, on these transcription factors.
METHODS: CsA (15 mg/kg/day) was administered subcutaneously daily to rats maintained on a low-sodium diet for 7, 14, and 28 days. DNA-binding activities of AP-1 and NF-kappaB in renal cortex were determined by electrophoretic mobility shift assay.
RESULTS: DNA-binding activity of AP-1 and NF-kappaB started to increase at day 14 and further elevated at day 28 by CsA treatment. These activations were markedly attenuated when rats were maintained on a high-Mg diet. In contrast, angiotensin-converting enzyme inhibitor (ACEI) had no effect on CsA-induced AP-1 activation. CsA-induced activation of NF-kappaB was suppressed by ACEI at day 14, whereas such effect could not be observed at day 28.
CONCLUSIONS: Renal cortical AP-1 and NF-kappaB DNA binding were activated in chronic CsA nephrotoxicity. These activations were induced largely by means of RAS-independent mechanisms. It is suggested that prevention of CsA-induced DNA-binding activation of these transcription factors is at least in part responsible for the beneficial effects of Mg supplementation on CsA nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12698095     DOI: 10.1097/01.TP.0000057242.96219.AF

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway.

Authors:  Jianmin Xu; Stephanie B Walsh; Zoe M Verney; Levy Kopelovich; Craig A Elmets; Mohammad Athar
Journal:  Biochem Biophys Res Commun       Date:  2011-02-17       Impact factor: 3.575

2.  Association of magnesium abnormalities at intensive care unit admission with kidney outcomes and mortality: a prospective cohort study.

Authors:  Heitor S Ribeiro; Emmanuel A Burdmann; Edilene A Vieira; Mateus L Ferreira; Aparecido P Ferreira; Antônio J Inda-Filho
Journal:  Clin Exp Nephrol       Date:  2022-06-27       Impact factor: 2.617

Review 3.  Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl.

Authors:  Peter A McCullough; Sajid Ali
Journal:  Drug Des Devel Ther       Date:  2012-06-14       Impact factor: 4.162

Review 4.  Serum Magnesium after Kidney Transplantation: A Systematic Review.

Authors:  Anne-Sophie Garnier; Agnès Duveau; Martin Planchais; Jean-François Subra; Johnny Sayegh; Jean-François Augusto
Journal:  Nutrients       Date:  2018-06-06       Impact factor: 5.717

5.  Relationship between dietary magnesium intake and rheumatoid arthritis in US women: a cross-sectional study.

Authors:  Congqi Hu; Fangfang Zhu; Lijuan Liu; Mingying Zhang; Guangxing Chen
Journal:  BMJ Open       Date:  2020-11-09       Impact factor: 2.692

Review 6.  Established and newly proposed mechanisms of chronic cyclosporine nephropathy.

Authors:  Hye Eun Yoon; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 2.884

7.  Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model.

Authors:  Shinya Morita; Kazunobu Shinoda; Tadashi Yoshida; Masayuki Shimoda; Yoshihiko Kanno; Ryuichi Mizuno; Hidaka Kono; Hiroshi Asanuma; Ken Nakagawa; Kazuo Umezawa; Mototsugu Oya
Journal:  BMC Pharmacol Toxicol       Date:  2020-08-12       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.